Cargando…

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism

Congenital hyperinsulinism (HI) is a genetic disorder in which pancreatic β-cell insulin secretion is excessive and results in hypoglycemia that, without treatment, can cause brain damage or death. Most patients with loss-of-function mutations in ABCC8 and KCNJ11, the genes encoding the β-cell ATP-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterson, Sean M., Juliana, Christine A., Hu, Cameron F., Chai, Jinghua, Holliday, Carson, Chan, Kara Y., Lujan Hernandez, Ana G., Challocombe, Zoe, Wang, Linya, Han, Zhen, Haas, Nikhil, Stafford, Ryan, Axelrod, Fumiko, Yuan, Tom Z., De León, Diva D., Sato, Aaron K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2023
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450825/ https://www.ncbi.nlm.nih.gov/pubmed/37358194 http://dx.doi.org/10.2337/db22-1039

Ejemplares similares

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism
por: Juliana, Christine A., et al.
Publicado: (2023)

Activation of Protein Kinase A (PKA) signaling mitigates congenital hyperinsulinism associated hypoglycemia in the Sur1(-/-) mouse model
por: Soundarapandian, Mangala M., et al.
Publicado: (2020)

The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism
por: Danowitz, Melinda, et al.
Publicado: (2022)

Mosaic GLUD1 Mutations Associated with Hyperinsulinism Hyperammonemia Syndrome
por: Boodhansingh, Kara E., et al.
Publicado: (2022)

Phenotypic Characterization of Congenital Hyperinsulinism Due to Novel Activating Glucokinase Mutations
por: Li, Changhong, et al.
Publicado: (2023)

Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient
por: Banerjee, Indraneel, et al.
Publicado: (2017)

Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series
por: Salomon-Estebanez, Maria, et al.
Publicado: (2020)

Corrigendum: Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series
por: Salomon-Estebanez, Maria, et al.
Publicado: (2020)

Hyperinsulinism
Publicado: (1932)

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
por: Umapathysivam, Mahesh M., et al.
Publicado: (2014)

Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome
por: Rosenfeld, Elizabeth, et al.
Publicado: (2022)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle
por: Dineen, Stacey L., et al.
Publicado: (2015)

GLP-1 Receptor Antagonist Exendin-(9-39) Elevates Fasting Blood Glucose Levels in Congenital Hyperinsulinism Owing to Inactivating Mutations in the ATP-Sensitive K(+) Channel
por: Calabria, Andrew C., et al.
Publicado: (2012)

Natural history and neurodevelopmental outcomes in perinatal stress induced hyperinsulinism
por: Sigal, Winnie M., et al.
Publicado: (2022)

Transient Receptor Potential Vanilloid 1 Activation Enhances Gut Glucagon-Like Peptide-1 Secretion and Improves Glucose Homeostasis
por: Wang, Peijian, et al.
Publicado: (2012)

Correction: Characterizing the neurological phenotype of the hyperinsulinism hyperammonemia syndrome
por: Rosenfeld, Elizabeth, et al.
Publicado: (2022)

SAT-272 A Phase 2 Comparison of a Stable Liquid Glucagon to Placebo for the Treatment of Congenital Hyperinsulinism
por: Thornton, Paul, et al.
Publicado: (2019)

Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
por: Edgerton, Dale S., et al.
Publicado: (2009)

Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
por: Cummings, Bethany P., et al.
Publicado: (2010)

Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells
por: Peduto Eberl, L, et al.
Publicado: (2003)

Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers
por: Bajo, A M, et al.
Publicado: (2004)

Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review
por: Moore, Thomas J., et al.
Publicado: (2022)

MON-087 Natural History and Neurodevelopmental Outcomes in Perinatal Stress Induced Hyperinsulinism
por: Sigal, Winnie M, et al.
Publicado: (2020)

Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
por: Banerjee, Indraneel, et al.
Publicado: (2022)

Novel dominant K(ATP) channel mutations in infants with congenital hyperinsulinism: Validation by in vitro expression studies and in vivo carrier phenotyping
por: Boodhansingh, Kara E., et al.
Publicado: (2019)

OR05-2 Targeted Inhibition of Glutamate Dehydrogenase by Alpha-Tocopherol: A Potential Novel Treatment for Hyperinsulinism Hyperammonemia Syndrome
por: Rosenfeld, Elizabeth, et al.
Publicado: (2019)

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086
por: Cellai, C, et al.
Publicado: (2006)

Correction to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
por: Banerjee, Indraneel, et al.
Publicado: (2022)

A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism
por: Heo, Yong Ho, et al.
Publicado: (2022)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Case Report: Two Distinct Focal Congenital Hyperinsulinism Lesions Resulting From Separate Genetic Events
por: Rosenfeld, Elizabeth, et al.
Publicado: (2021)

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
por: Zakaria, Z, et al.
Publicado: (2016)

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies
por: Christiansen, Mark P, et al.
Publicado: (2021)

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
por: Castle, Jessica R., et al.
Publicado: (2015)

An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium
por: Keedwell, R G, et al.
Publicado: (2004)

Familial Focal Congenital Hyperinsulinism
por: Ismail, Dunia, et al.
Publicado: (2011)

Global Registries in Congenital Hyperinsulinism
por: Pasquini, Tai L. S., et al.
Publicado: (2022)

Syndromic forms of congenital hyperinsulinism
por: Zenker, Martin, et al.
Publicado: (2023)

Congenital Hyperinsulinism International: A Community Focused on Improving the Lives of People Living With Congenital Hyperinsulinism
por: Raskin, Julie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n82bjq0th150nlt46kiddmqvhh